June 8 (Reuters) - GSK plc GSK.L:

• ENGITIX ANNOUNCES STRATEGIC COLLABORATION WITH GSK TO ADVANCE FIRST-IN-CLASS TARGETS FOR LIVER FIBROSIS REGRESSION

• ENGITIX: UNDER TERMS, CO IS ELIGIBLE TO GET UP TO £44.5 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS

• ENGITIX: GSK WILL HAVE OPTION TO LICENSE ASSAYS, DATASETS, AND TARGETS ARISING FROM COLLABORATION

• ENGITIX: UNDER TERMS, CO ALSO ELIGIBLE FOR UP TO £118 MILLION PER TARGET IN DOWNSTREAM MILESTONE PAYMENTS

Source text: ID:nGNX277H2Z

Further company coverage: GSK.L